Nordic Enterprises See SDN as Key to Network Agility, Working from Home
5.7.2021 11:00:00 EEST | Business Wire | Press release
Enterprises in the Nordics are expanding their adoption of software-defined networking technology to become more agile and flexible while enabling employees to more easily work from home, according to a new report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm.
The 2021 ISG Provider Lens™ Network – Software Defined Solutions and Services Report for the Nordics finds enterprises in the region looking to SDN-related technologies and service providers to help them with challenges related to the flexibility, speed and collaboration they need to better serve their employees and their increasingly mobile customers.
“Nordic enterprises are looking to SDN and its service providers to increase their network agility, flexibility and competitiveness while enabling remote working and better business continuity,” said Jan Erik Aase, partner and global leader, ISG Provider Lens Research. “This new need for enterprise agility goes beyond the abilities of traditional networks in a constantly changing competitive environment.”
The report also sees enterprises in the region embracing SD-WAN to enable remote working. While WAN architecture at enterprises has created backhaul challenges, that architecture is evolving to support more connectivity choices. Vendors are enabling enterprises to use a variety of transport options actively or on standby.
In addition, Nordic enterprises are moving toward more automation and analytics. Enterprises are increasingly embracing the concept of the network as code, where changes in the network infrastructure can be handled through code changes. Service providers are leveraging automation tools and allowing visibility into the cloud, the data center, and the WAN. Nordic enterprises see SD-WAN as a way to drive automation, reduce reliance on network hardware and consolidate network functionality.
Nordic enterprises are also seeking end-to-end connectivity to analyze data at the edge, including data generated by Internet of Things (IoT) devices, the report says. Service providers and system integrators are exploring ways to bring new capabilities to Wi-Fi 6, long-term evolution (LTE) and fifth-generation (5G) networks. They are also looking to assist customers with large public 5G rollouts, with some spectrum potentially allocated for enterprises.
New SDN-related technologies will pave the way for the industrial IoT to scale up and for edge computing to grow further, the report adds. However, a more inclusive network ecosystem is needed for the cloud, which is evolving into a holistic web of network technologies that include components of SDN such as WAN, LAN and Wi-Fi 6 management.
The report also sees changes in network practices driven in part by the move in the Nordics to the cloud and to the software-as-a-service model. Enterprises there have been seeing more internet-based traffic, which has led them to consider new ways to look at connectivity. Enterprises are moving away from a conventional hub-and-spoke networking model and considering instead an any-to-any connectivity model that supports more cloud-oriented traffic patterns.
The 2021 ISG Provider Lens™ Network – Software Defined Solutions and Services Report for the Nordics evaluates the capabilities of 55 providers across six quadrants: Managed (SD) WAN Services, SDN Transformation Services (Consulting and Implementation), SD-WAN Equipment and Service Suppliers (DIY), Technology and Service Suppliers (Core – 4G/5G), Edge Technology and Services, and Enterprise 5G Solutions.
The report names Orange Business Services as a leader in five quadrants and BT, Cisco, Deutsche Telekom, HCL, IBM, Tech Mahindra and Wipro as leaders in four. Ericsson, HPE Aruba and Nuage Networks are named leaders in three quadrants, and Infosys, TCS, Telenor, Telia, Verizon and VMware are named leaders in two. Citrix, Juniper Networks, Nokia Networks and Versa Networks are named leaders in one quadrant.
In addition, Tech Mahindra, Verizon and Wipro were named Rising Stars—companies with “promising portfolios” and “high future potential” by ISG’s definition—in two quadrants. GTT and Infosys were named Rising Stars in one quadrant each.
The 2021 ISG Provider Lens™ Network – Software Defined Solutions and Services Report for the Nordics is available to subscribers or for one-time purchase on this webpage.
About ISG Provider Lens™ Research
The ISG Provider Lens™ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Germany, Switzerland, the U.K., France, the Nordics, Brazil and Australia/New Zealand, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage.
A companion research series, the ISG Provider Lens Archetype reports, offer a first-of-its-kind evaluation of providers from the perspective of specific buyer types.
About ISG
ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 700 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210705005021/en/
Contact information
Will Thoretz, ISG
+1 203 517 3119
will.thoretz@isg-one.com
Erik Arvidson, Matter Communications for ISG
+1 617 755 2985
isg@matternow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
